Pharmamarketeer

European Commission approves new indication for Dupixent in chronic rhinosinusitis with nasal polyposis

The European Commission (EC), approved a new indication for Dupixent (dupilumab) in chronic rhinosinusitis with nasal polyposis (CRSwNP). Dupixent is indicated as an add─on therapy with intranasal corticosteroids

Advertentie(s)
Geen nieuws missen?
Volg de duizenden farma professionals die Pharmamarkteer.nl via e-mail lezen

Uw inschrijving is gelukt.
Bedankt!
Naar Pharmamarkteer.nl